Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Companies Should Reward Consistent Compliance with Detailing Guidelines in Performance Evaluations: MHLW Study
Most drug makers and wholesalers are setting up systems to comply with the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines, but reflecting the appropriateness of detailing activities in the performance evaluations of officials and employees has been…
To read the full story
Related Article
- Over 30% of Drug Makers Spot Inappropriate Promotions after Guidelines Enforcement
June 16, 2021
- MHLW to Run Fresh Survey on Drug Makers’ Responses to Promotion Guidelines
January 13, 2021
- Promotion Guidelines Now in Full Effect, MHLW Starts Survey to Capture Leading Examples of Company Set-Ups
December 17, 2019
REGULATORY
- Government Unveils Four-Chapter Outline for 2026 Honebuto
June 26, 2026
- LDP, Ishin Leave Chuikyo Reform to Party Negotiators after Talks Stall
June 26, 2026
- Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
- Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
- Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…